Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study-Reference-Cited by-同舟云学术

Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study

Published:2018-12-08 Issue:2 Volume:83 Page:375-385
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Pavel Marianne,Borson-Chazot Françoise,Cailleux Anne,Hörsch Dieter,Lahner Harald,Pivonello Rosario,Tauchmanova Libuse,Darstein Christelle,Olsson Håkan,Tiberg Fredrik,Ferone Diego

Funder

Camurus in collaboration with Novartis Pharma AG.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3734-1/fulltext.html

Reference18 articles.

1. Pavel M, Kidd M, Modlin I (2013) Systemic therapeutic options for carcinoid. Semin Oncol 40(1):84–99. https://doi.org/10.1053/j.seminoncol.2012.11.003

2. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951. https://doi.org/10.1210/jc.2014-2700

3. Anthony L, Freda PU (2009) From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 25(12):2989–2999. https://doi.org/10.1185/03007990903328959

4. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R, Group PS (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol Off J Am Soc Clin Oncol 27(28):4656–4663. https://doi.org/10.1200/JCO.2009.22.8510

5. Kulke MH, Shah MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW 2nd, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D, National comprehensive cancer n (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw 13 (1):78–108

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine;Best Practice & Research Clinical Endocrinology & Metabolism;2024-07

2. Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use;Expert Review of Endocrinology & Metabolism;2024-06-06

3. Medical treatment of functional pituitary adenomas, trials and tribulations;Journal of Neuro-Oncology;2024-05-18

4. Investigational drugs for the treatment of acromegaly: new agents to transform therapy;Expert Opinion on Investigational Drugs;2024-04-30

5. Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide;Endocrine;2024-02-29